Neukio Biotherapeutics focuses on developing and commercializing immune cell therapies, specifically iPSC-derived off-the-shelf CAR-NK products intended to treat solid tumors. The company aims to design a scalable allogeneic cell-therapy manufacturing approach to produce off-the-shelf treatments. Neukio plans to use new funding to accelerate preclinical and clinical validation of its iPSC-CAR-NK pipeline and to support team recruitment and expansion. Led by CEO Dr. Richard Liqun Wang, the management team has established an iPSC-CAR-NK-based pipeline development strategy. Since its founding in June 2021, the company reports rapid progress in talent recruitment, facility construction, R&D pipeline advancement and quality-management system establishment. The firm emphasizes in-house R&D to deliver clinical solutions for cancer patients worldwide. Neukio Biotherapeutics focuses on developing and commercializing allogeneic off-the-shelf cell therapies built on an iPSC-CAR-NK platform. The company pursues a combined approach of in-house innovation and external collaboration with world-leading partners. Planned use of proceeds includes establishment of a research facility and further development of immune cell technology platforms and therapeutic assets. Neukio positions its pipeline to address cancer patients worldwide through scalable universal products. The company launched from the Life Science Park of the Shanghai Free Trade Zone. Dr. Richard Wang, founder, chairman and CEO, brings extensive R&D and management experience in the US and China, including leadership roles at Fosun Kite and work on Yescarta's tech transfer and regulatory milestones.

Total raised

$90M

Funding rounds

2

Latest round

Series A

Latest activity

Sep 2022